Coronado Industries Retains OTC Financial Network to Lead Comprehensive Investor Relations Campaign.

Business/Technology Editors

FOUNTAIN HILLS, Ariz.--(BUSINESS WIRE)--Jan. 11, 2000

Coronado Industries, Inc. (OTC BB:CDIK), a manufacturer of proprietary pneumatic devices for the effective treatment of glaucoma, today announced that it has selected OTC Financial Network, a division of National Financial Communications Corp. (NFC) of Needham, Massachusetts, to direct its financial communications and shareholder relations campaign.

Geoffrey J. Eiten, president of National Financial Communications, commented, "This is an exciting time for Coronado. The Company is making significant headway in the fight against glaucoma, a disease that afflicts 66 million people worldwide. We look forward to communicating Coronado's ground-breaking advancements to investors."

Coronado Industries, through its wholly-owned subsidiaries American Glaucoma and Opthalmic International, focuses on the development and testing of a patented procedure, Pneumatic Trabeculoplasty (PNT(tm)), a non-invasive, highly effective, and low-cost alternative to traditional treatments.

Currently, the Company markets its pneumatic suction device and treatment throughout the European marketplace under a CE Mark (allowing manufacturers to freely sell their products) from the European Commission. Pending FDA approval, the Company will license its patented treatment procedure and equipment in the United States.

President of Coronado Industries, Gary Smith, stated, "Working with OTC Financial Network will enable us to get our story out to the investment community. We continue to experience success with our PNT trials in China, where 100% of participants experienced lowered intraocular pressure. These results represent a giant step towards making our devices and treatment available worldwide."

Smith continued, "We were also extremely pleased by the results of our PNT study conducted at the Arizona Glaucoma Institute. More than half the participants were able to stop using their medication and still maintain lowered pressure on their ocular nerve. The remaining participants were able to achieve the same results by reducing their medication by 50%. These numbers are significant in light of the frequent side effects accompanying the use of traditional treatments, such as eye drops or surgery."

Coronado Industries' PNT treatment is designed to treat the two most common types of glaucoma - open-angle and pigmentary glaucoma. A suction device, applied to the eye for one to two minutes, reduces intraocular pressure non-evasively, and without side effects. After four years' evaluation of PNT/glaucoma trial results, the treatment has been proven to offer some value in the treatment of ocular hypertension as well.

OTC Financial Network, a division of National Financial Communications Corp., is a financial communications and investor relations firm specializing in the representation of micro-cap companies.

Forward-looking statements in this release are made pursuant to the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. Investors are cautioned that such forward-looking statements involve risks and uncertainties, including without limitation, continued acceptance of the Company's products, increased levels of competition for the Company, new products and technological changes, the Company's dependence on third-party suppliers, and other risks detailed from time to time in the Company's periodic reports filed with the Securities and Exchange Commission.

For additional information, see www.coronadoindustries.com